Millions of Type 1 Diabetics and insulin-dependent individuals rely on Continuous Glucose Monitors (CGMs) to stay alive every single day. A CGM is not a luxury gadget or a minor convenience; it is a critical piece of life-sustaining medical equipment.

For years, the Dexcom G6 has been the gold standard of reliability, providing accurate data and seamless integration with Automated Insulin Delivery (AID) systems like the Tandem t:slim X2.

Despite this, Dexcom has announced it will permanently discontinue manufacturing the G6 on July 1, 2026, forcing thousands of highly vulnerable patients to upgrade to the G7 or G7 15-Day sensors.

For a vast pool of users, the G7 platform is fundamentally flawed, buggy, and dangerous. Across patient communities, thousands of users have reported a catastrophic drop in quality control, including:

• The "Silent Fix" Gamble: Dexcom customer support routinely dismisses systemic failures by claiming they are continuously integrating rolling "product improvements". Yet, without a transparent, nationwide recall of known defective batches, patients are left playing Russian roulette with their medical supplies. There is zero consumer verification to prove whether a newly dispensed box contains a corrected device or a legacy defect.
• Frequent Early Failures and Signal Drops: Sensors regularly fail, disconnect, or drop Bluetooth signal long before their intended lifespan expires. For Tandem pump users, frequent signal dropouts disrupt closed-loop automated insulin suspension, leading to terrifying spikes and drops in blood sugar.
• Severe Inaccuracy: Both the 10-day and newly released 15-day G7 sensors are regularly reported to be off by 40+ points, frequently generating false lows or masking dangerous hyperglycemia. Relying on inaccurate data to calculate automated insulin doses can lead to severe hypoglycemia, coma, or even death.
• Regulatory Recalls: This is not a matter of a few loud complaints on social media. The FDA has already stepped in with severe Class I recalls addressing silent receiver speakers and G7 mobile application bugs that completely failed to alert patients when their transmitter unexpectedly shut down.
• Unacceptable Administrative Hurdles: When these devices inevitably fail early, patients are forced to sit on exhausting, half-hour technical support calls just to beg for a replacement. For a device that serves as a literal lifeline, forcing consumers to wade through corporate gatekeeping to replace defective hardware is a systemic failure of patient care.

We refuse to be forced into an expanding pool of justifiably angry customers. We should not be used as beta-testers for unstable hardware while Dexcom focuses resources on marketing lifestyle products like Stelo.

A Message from a Veteran T1D: Forcing Us Backwards is a Betrayal

As the creator of this petition, I have lived with Type 1 Diabetes for more than 44 years. I have been on an insulin pump for 24. For decades, this disease has been perplexing, frustrating, and unpredictable, and it has never stayed in the background for very long. It has held an absolute veto power over every major milestone and turning point in my life, forcing every career decision to revolve around my survival. It has been incredibly treacherous. I have survived two car accidents caused by "hypoglycemic unawareness," when I didn't recognize symptoms that my sugar was crashing out. I've had to be  resuscitated by EMTs a number of times, including once when I'd gone unconscious and began seizing after my blood sugar plummeted to a catastrophic 19.  I know exactly how fast this disease can turn fatal.

Only when I incorporated the Dexcom G6 into my treatment was I finally able to maintain blood glucose control that is anything close to normal. The difference has been enormous: I have maintained an A1C at 6.4% or below for the past five years. I cannot stress enough how much I depend upon the G6 for that success.

My experience trying to transition to the G7 was miserable. Out of a single three-pack box, the first sensor repeatedly disconnected and finally failed permanently on day 3. The next two sensors both failed within six days of placement. 

I am not willing to take steps backward. Not at my age, and not after fighting this disease for all this time. To take away the one reliable device that finally gave me control over my own survival is the ultimate betrayal.

Our Clear Demands:

1. Extend G6 Production: Delay the July 1, 2026 discontinuation of the Dexcom G6 indefinitely until the hardware and software stability of the G7 platform is demonstrably fixed and verified by the community.
2. Resolve AID Integration Faults: Coordinate directly with Tandem and other pump partners to completely resolve the localized Bluetooth signal drops interrupting closed-loop systems.
3. Transparent Safety Investigation: We call on the FDA to review the exponentially growing volume of consumer complaints, sensor failures, and adverse event reports regarding G7 inaccuracies.
4. Issue a National Recall and Pull Defective Batches: Immediately halt the distribution of all unverified, buggy G7 sensor lots currently sitting on pharmacy shelves. Dexcom must institute a transparent nationwide recall of all batches manufactured prior to their unverified "product improvements." Do not set your customer base up to fail. This is seriously a life-vs-death issue for Type 1 Diabetics, and it needs to be treated as such.

Do not take away our lifeline. Keep the Dexcom G6 in production.